{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T23:37:49Z","timestamp":1777765069611,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Skin cutaneous melanoma is a malignant and highly metastatic skin tumor, and its morbidity and mortality are still rising worldwide. However, the molecular mechanisms that promote melanoma metastasis are unclear. Two datasets (GSE15605 and GSE46517) were retrieved to identify the differentially expressed genes (DEGs), including 23 normal skin tissues (N), 77 primary melanoma tissues (T) and 85 metastatic melanoma tissues (M). Gene ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analysis were performed to explore the functions of the DEGs. We constructed protein\u2013protein interaction network using the STRING database and Cytoscape software. Using the cytoHubba plugin of Cytoscape, we identified the most significant hub genes by five analytical methods (Degree, Bottleneck, MCC, MNC, and EPC). Hub gene expression was validated using the UALCAN website. Clinical relevance was investigated using The Cancer Genome Atlas resources. Finally, we explored the association between metastasis-associated genes and immune infiltrates through the Tumor Immune Estimation Resource (TIMER) database and performed drug\u2013gene interaction analysis using the Drug-Gene Interaction database. A total of 294 specific genes were related to melanoma metastasis and were mainly involved in the positive regulation of locomotion, mitotic cell cycle process, and epithelial cell differentiation. Four hub genes (CDK1, FOXM1, KIF11, and RFC4) were identified from the cytoHubba plugin of Cytoscape. CDK1 was significantly upregulated in metastatic melanoma compared with primary melanoma, and high CDK1 expression was positively correlated with worse overall survival. Immune infiltration analysis revealed that CDK1 expression negatively correlated with macrophage infiltration (Rho\u2009=\u2009\u2212\u20090.164, <jats:italic>P<\/jats:italic>\u2009=\u20092.02e\u221203) and positively correlated with neutrophil cells (Rho\u2009=\u20090.269, <jats:italic>P<\/jats:italic>\u2009=\u20092.72e\u221207) in SKCM metastasis. In addition, we identified that CDK1 had a close interaction with 10 antitumor drugs. CDK1 was identified as a hub gene involved in the progression of melanoma metastasis and may be regarded as a therapeutic target for melanoma patients to improve prognosis and prevent metastasis in the future.<\/jats:p>","DOI":"10.1038\/s41598-022-17468-6","type":"journal-article","created":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T10:04:36Z","timestamp":1659089076000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Exploration and validation of metastasis-associated genes for skin cutaneous melanoma"],"prefix":"10.1038","volume":"12","author":[{"given":"Hong","family":"Luan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linge","family":"Jian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,29]]},"reference":[{"issue":"1","key":"17468_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 70(1), 7\u201330 (2020).","journal-title":"CA Cancer J. Clin."},{"issue":"10151","key":"17468_CR2","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","volume":"392","author":"D Schadendorf","year":"2018","unstructured":"Schadendorf, D. et al. Melanoma. Lancet 392(10151), 971\u2013984 (2018).","journal-title":"Lancet"},{"issue":"11","key":"17468_CR3","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1080\/15384047.2019.1640032","volume":"20","author":"LE Davis","year":"2019","unstructured":"Davis, L. E., Shalin, S. C. & Tackett, A. J. Current state of melanoma diagnosis and treatment. Cancer Biol. Ther. 20(11), 1366\u20131379 (2019).","journal-title":"Cancer Biol. Ther."},{"issue":"3","key":"17468_CR4","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3892\/ijo.2020.5088","volume":"57","author":"GC Leonardi","year":"2020","unstructured":"Leonardi, G. C. et al. Cutaneous melanoma and the immunotherapy revolution (review). Int. J. Oncol. 57(3), 609\u2013618 (2020).","journal-title":"Int. J. Oncol."},{"issue":"3","key":"17468_CR5","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/s41416-020-01121-y","volume":"124","author":"P Bhave","year":"2021","unstructured":"Bhave, P. et al. Melanoma recurrence patterns and management after adjuvant targeted therapy: A multicentre analysis. Br. J. Cancer 124(3), 574\u2013580 (2021).","journal-title":"Br. J. Cancer"},{"key":"17468_CR6","first-page":"3","volume":"107","author":"V Brower","year":"2015","unstructured":"Brower, V. Checkpoint blockade immunotherapy for cancer comes of age. J. Natl. Cancer Inst. 107, 3 (2015).","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"17468_CR7","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/1346-8138.15804","volume":"48","author":"H Uhara","year":"2021","unstructured":"Uhara, H. et al. Five-year survival with nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma. J. Dermatol. 48(5), 592\u2013599 (2021).","journal-title":"J. Dermatol."},{"issue":"2","key":"17468_CR8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S1470-2045(18)30016-0","volume":"19","author":"PA Ascierto","year":"2018","unstructured":"Ascierto, P. A. & Eggermont, A. M. M. Neoadjuvant therapy in melanoma: The next step?. Lancet. Oncol. 19(2), 151\u2013153 (2018).","journal-title":"Lancet. Oncol."},{"issue":"4","key":"17468_CR9","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma, P. et al. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168(4), 707\u2013723 (2017).","journal-title":"Cell"},{"key":"17468_CR10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ejca.2017.06.028","volume":"83","author":"S Ugurel","year":"2017","unstructured":"Ugurel, S. et al. Survival of patients with advanced metastatic melanoma: The impact of novel therapies-update 2017. Eur. J. Cancer 83, 247\u2013257 (2017).","journal-title":"Eur. J. Cancer"},{"issue":"11","key":"17468_CR11","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1038\/jid.2013.197","volume":"133","author":"L Raskin","year":"2013","unstructured":"Raskin, L. et al. Transcriptome profiling identifies HMGA2 as a biomarker of melanoma progression and prognosis. J. Invest. Dermatol. 133(11), 2585\u20132592 (2013).","journal-title":"J. Invest. Dermatol."},{"issue":"5","key":"17468_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010770","volume":"5","author":"O Kabbarah","year":"2010","unstructured":"Kabbarah, O. et al. Integrative genome comparison of primary and metastatic melanomas. PLoS ONE 5(5), e10770 (2010).","journal-title":"PLoS ONE"},{"key":"17468_CR13","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1093\/nar\/gku1003","volume":"43","author":"D Szklarczyk","year":"2015","unstructured":"Szklarczyk, D. et al. STRING v10: Protein\u2013protein interaction networks integrated over the tree of life. Nucleic Acids. Res. 43, 447\u2013452 (2015).","journal-title":"Nucleic Acids. Res."},{"issue":"11","key":"17468_CR14","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon, P. et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome. Res. 13(11), 2498\u20132504 (2003).","journal-title":"Genome. Res."},{"issue":"4","key":"17468_CR15","first-page":"1","volume":"8","author":"CH Chin","year":"2014","unstructured":"Chin, C. H. et al. cytoHubba: Identifying hub objects and sub-networks from complex interactome. BMC Syst. Biol. 8(4), 1\u20137 (2014).","journal-title":"BMC Syst. Biol."},{"issue":"6","key":"17468_CR16","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","volume":"38","author":"MJ Goldman","year":"2020","unstructured":"Goldman, M. J. et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat. Biotechnol. 38(6), 675\u2013678 (2020).","journal-title":"Nat. Biotechnol."},{"key":"17468_CR17","doi-asserted-by":"publisher","first-page":"6352","DOI":"10.1126\/science.aan2507","volume":"357","author":"M Uhlen","year":"2017","unstructured":"Uhlen, M. et al. A pathology atlas of the human cancer transcriptome. Science 357, 6352 (2017).","journal-title":"Science"},{"issue":"21","key":"17468_CR18","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","volume":"77","author":"T Li","year":"2017","unstructured":"Li, T. et al. TIMER: A web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 77(21), e108\u2013e110 (2017).","journal-title":"Cancer Res."},{"key":"17468_CR19","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1093\/nar\/gkaa1084","volume":"49","author":"SL Freshour","year":"2021","unstructured":"Freshour, S. L. et al. Integration of the drug\u2013gene interaction database (DGIdb 4.0) with open crowdsource efforts. Nucleic Acids. Res. 49, 1144\u20131151 (2021).","journal-title":"Nucleic Acids. Res."},{"issue":"4","key":"17468_CR20","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1093\/carcin\/bgq030","volume":"31","author":"YL Hsu","year":"2010","unstructured":"Hsu, Y. L. et al. Phospholipase D signaling pathway is involved in lung cancer-derived IL-8 increased osteoclastogenesis. Carcinogenesis 31(4), 587\u2013596 (2010).","journal-title":"Carcinogenesis"},{"key":"17468_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.canlet.2021.04.014","volume":"511","author":"Y Nagumo","year":"2021","unstructured":"Nagumo, Y. et al. PLD1 promotes tumor invasion by regulation of MMP-13 expression via NF-kappaB signaling in bladder cancer. Cancer Lett. 511, 15\u201325 (2021).","journal-title":"Cancer Lett."},{"issue":"1","key":"17468_CR22","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.bbagrm.2011.09.004","volume":"1819","author":"CY Koo","year":"2012","unstructured":"Koo, C. Y., Muir, K. W. & Lam, E. W. FOXM1: From cancer initiation to progression and treatment. Biochim. Biophys. Acta 1819(1), 28\u201337 (2012).","journal-title":"Biochim. Biophys. Acta"},{"key":"17468_CR23","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/1471-2407-13-327","volume":"13","author":"MM Yung","year":"2013","unstructured":"Yung, M. M. et al. Activation of AMPK inhibits cervical cancer cell growth through AKT\/FOXO3a\/FOXM1 signaling cascade. BMC Cancer 13, 327 (2013).","journal-title":"BMC Cancer"},{"key":"17468_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.semcancer.2017.11.018","volume":"50","author":"S Yao","year":"2018","unstructured":"Yao, S., Fan, L. Y. & Lam, E. W. The FOXO3-FOXM1 axis: A key cancer drug target and a modulator of cancer drug resistance. Semin. Cancer Biol. 50, 77\u201389 (2018).","journal-title":"Semin. Cancer Biol."},{"issue":"11","key":"17468_CR25","doi-asserted-by":"publisher","first-page":"5955","DOI":"10.3390\/ijms22115955","volume":"22","author":"NR Lee","year":"2021","unstructured":"Lee, N. R. et al. Inactivation of the Akt\/FOXM1 signaling pathway by panobinostat suppresses the proliferation and metastasis of gastric cancer cells. Int. J. Mol. Sci. 22(11), 5955 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"17468_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.464","volume":"5","author":"I Neganova","year":"2014","unstructured":"Neganova, I. et al. CDK1 plays an important role in the maintenance of pluripotency and genomic stability in human pluripotent stem cells. Cell Death Dis. 5, e1508 (2014).","journal-title":"Cell Death Dis."},{"key":"17468_CR27","doi-asserted-by":"publisher","first-page":"11271","DOI":"10.2147\/CMAR.S255895","volume":"12","author":"Y Zhu","year":"2020","unstructured":"Zhu, Y. et al. Inhibition of CDK1 Reverses the Resistance of 5-Fu in Colorectal Cancer. Cancer Manag. Res. 12, 11271\u201311283 (2020).","journal-title":"Cancer Manag. Res."},{"issue":"9","key":"17468_CR28","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1007\/s12094-021-02575-z","volume":"23","author":"Z Huang","year":"2021","unstructured":"Huang, Z., Shen, G. & Gao, J. CDK1 promotes the stemness of lung cancer cells through interacting with Sox2. Clin. Transl. Oncol. 23(9), 1743\u20131751 (2021).","journal-title":"Clin. Transl. Oncol."},{"issue":"1","key":"17468_CR29","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201910880","volume":"12","author":"J Heo","year":"2020","unstructured":"Heo, J. et al. Phosphorylation of TFCP2L1 by CDK1 is required for stem cell pluripotency and bladder carcinogenesis. EMBO Mol. Med. 12(1), e10880 (2020).","journal-title":"EMBO Mol. Med."},{"issue":"23","key":"17468_CR30","doi-asserted-by":"publisher","first-page":"6561","DOI":"10.1158\/0008-5472.CAN-18-0330","volume":"78","author":"D Ravindran Menon","year":"2018","unstructured":"Ravindran Menon, D. et al. CDK1 Interacts with sox2 and promotes tumor initiation in human melanoma. Cancer Res. 78(23), 6561\u20136574 (2018).","journal-title":"Cancer Res."},{"issue":"1","key":"17468_CR31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100(1), 57\u201370 (2000).","journal-title":"Cell"},{"issue":"3","key":"17468_CR32","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","volume":"21","author":"D Hanahan","year":"2012","unstructured":"Hanahan, D. & Coussens, L. M. Accessories to the crime: Functions of cells recruited to the tumor microenvironment. Cancer Cell 21(3), 309\u2013322 (2012).","journal-title":"Cancer Cell"},{"issue":"8","key":"17468_CR33","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1093\/annonc\/mdu191","volume":"25","author":"HR Ali","year":"2014","unstructured":"Ali, H. R. et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann. Oncol. 25(8), 1536\u20131543 (2014).","journal-title":"Ann. Oncol."},{"key":"17468_CR34","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3389\/fimmu.2014.00532","volume":"5","author":"M Rath","year":"2014","unstructured":"Rath, M. et al. Metabolism via arginase or nitric oxide synthase: Two competing arginine pathways in macrophages. Front. Immunol. 5, 532 (2014).","journal-title":"Front. Immunol."},{"issue":"5","key":"17468_CR35","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.immuni.2016.10.021","volume":"45","author":"M De Simone","year":"2016","unstructured":"De Simone, M. et al. Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating t regulatory cells. Immunity 45(5), 1135\u20131147 (2016).","journal-title":"Immunity"},{"issue":"7","key":"17468_CR36","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.18632\/oncotarget.1892","volume":"5","author":"E Shtivelman","year":"2014","unstructured":"Shtivelman, E. et al. Pathways and therapeutic targets in melanoma. Oncotarget 5(7), 1701\u20131752 (2014).","journal-title":"Oncotarget"},{"issue":"26","key":"17468_CR37","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364(26), 2507\u20132516 (2011).","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"17468_CR38","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1055\/a-1128-0280","volume":"80","author":"C Claussen","year":"2020","unstructured":"Claussen, C., Rody, A. & Hanker, L. Treatment of recurrent epithelial ovarian cancer. Geburtshilfe Frauenheilkd 80(12), 1195\u20131204 (2020).","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"5","key":"17468_CR39","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s00280-013-2113-1","volume":"71","author":"R Plummer","year":"2013","unstructured":"Plummer, R. et al. A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer Chemother. Pharmacol. 71(5), 1191\u20131199 (2013).","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"2","key":"17468_CR40","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1158\/1535-7163.MCT-19-0451","volume":"19","author":"X Xu","year":"2020","unstructured":"Xu, X. et al. Rational combination therapy for melanoma with dinaciclib by targeting BAK-dependent cell death. Mol. Cancer Ther. 19(2), 627\u2013636 (2020).","journal-title":"Mol. Cancer Ther."},{"issue":"9","key":"17468_CR41","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/s41419-020-02971-3","volume":"11","author":"M Stetkova","year":"2020","unstructured":"Stetkova, M. et al. CDK9 activity is critical for maintaining MDM4 overexpression in tumor cells. Cell Death Dis. 11(9), 754 (2020).","journal-title":"Cell Death Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17468-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17468-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17468-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T04:53:43Z","timestamp":1669352023000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17468-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,29]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["17468"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-17468-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,29]]},"assertion":[{"value":"11 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13002"}}